San Francisco, CA, February 28, 2022 — Feel Therapeutics Inc., a digital biomarkers and therapeutics company reinventing mental health with objective measurement, today announced the launch of Feel DTx, the world’s first data-driven digital therapeutic to treat patients with Major Depressive Disorder (MDD) and/or Generalized Anxiety Disorder (GAD). Feel DTx was launched under the FDA’s Enforcement Policy for Digital Health Devices For Treating Disorders During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency.
One out of four individuals struggles with a mental health condition. Currently, the treatment of mental health relies on subjective self-reported questionnaires and episodic clinic visits resulting in fragmented care and delayed intervention that costs the US healthcare system ~$500B annually. To address these issues, Feel Therapeutics developed Feel DTx to bring real-world data and measurement to the treatment and management of individuals struggling with mental health, easily accessible via their smartphone.
"Feel DTx is an end-to-end digital mental health solution that combines data-driven, personalized mental health interventions via the Feel Mobile App. Included in the app is a structured 16-week program based on cognitive behavioral therapy (in addition to elements from neuroscience and biopsychology), and video and text based support with board-certified health coaches,“ said George Eleftheriou, CEO and co-founder of Feel Therapeutics.
Designed as an adjunct to care for MDD and GAD, Feel DTx is readily accessible via both Android and iOS smartphone devices, and teaches patients new skills and behaviors to enable them to self-manage their anxiety and depression.
“Access to care is a problem in mental health. Patients often wait up to 6 months to be seen, which is not conducive to supporting the dynamic nature of mental health where timely intervention is critical. Feel DTx provides access and on-time interventions, supporting patients at their point of need,” said Haris Tsirmpas, Chief Technology Officer and co-founder of the company.
Feel DTx is offering digital cognitive behavioral therapy (CBT) through its Feel Mobile App, to reduce symptoms of MDD and GAD by providing cognitive restructuring and emotion regulating interventions and enabling individuals to self-manage their thoughts, feelings, and behaviors. The Feel App can be used as a standalone, or with an optional Feel Emotion Sensor, which uses the science of affective computing to help detect changes in the emotional state of a patient. Based on these emotional changes, Feel DTx provides interventions and psychoeducational material relevant to the emotional state of individuals during their day. Over the 16-week program, patients may benefit from:
Feel DTx includes
“Feel coaches receive quality data collected in real-time about their patients’ emotional state giving them unprecedented visibility into the mental health of their patients outside of sessions, which allows them to deliver effective interventions in a more efficient way,” said Sharon Kaplow, Vice President of Clinical Operations of the company.
Feel DTx is a digital therapeutic intended for adults in the U.S. 18 years or older who are experiencing Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD). Feel provides interventions based on cognitive behavioral therapy in addition to elements from neuroscience and biopsychology, educational content, emotion monitoring technology, and personalized interventions. Feel DTx reduces symptoms of MDD and GAD by providing cognitive restructuring and emotion regulating interventions to enable individuals to self-manage their thoughts, feelings, and behaviors.
For additional information and support, please visit
Feel Therapeutics, Inc. is developing Digital Biomarkers and Therapeutics to bring objective data and measurement in the way we diagnose, manage, and care for Mental Health. The company is backed by top-tier investors (Felicis, Anthemis, SOSV) and has partnerships with large pharmaceutical companies to develop novel digital biomarkers and bring digital health solutions to market as standalone programs or alongside medications. Feel Therapeutics is headquartered in San Francisco, with additional offices in Europe. For more information, visit http://www.feeltherapeutics.com or contact us at email@example.com.